Original Article

Immunogenicity of mannan derived from Mycobacterium bovis as a promising adjuvant in vaccine BCG

Abstract

Background and Objectives: Lipoarabinomannan is one of the components of the significant structural cell surfaces of mycobacteria and serves as an immunostimulatory factor. TNF-α and IL-12 are two examples of the anti-bacterial inflammatory cytokines that are activated and induced during infection.
Materials and Methods: In this study, mannan was extracted and processed, and then Bulb/c female mice were used in three groups, one group was given BCG vaccine, the other group was given BCG vaccine with mannan adjuvant, and a non-injected group was used as a control group. Inflammatory factors interleukin-12, TNF-α, IgG and IgM were measured in mouse serum.
Results: The levels of the inflammatory factors interleukin-12 and TNF-α in the serum isolated from mice receiving the BCG vaccine with mannan adjuvant showed a significant difference compared to the group that received only the BCG vaccine and the control group [IL-12] and , with P≤0.05.The examination of the level of IgG immune factors in these three groups revealed a significant difference. The group that received the BCG vaccine with mannan adjuvant showed a marked contrast compared to the group that received only the BCG vaccine and the control group, with P≤0.05. The level of IgM was higher in the group that received the BCG vaccine alone compared to the adjuvant vaccine group and the control group, with P≤0.05.
Conclusion: Our results indicated that mice receiving the BCG vaccine with mannan adjuvant had significantly higher serum levels of IL-12, TNF-α, and IgG than the group receiving BCG alone.

1. Ito T, Hasegawa A, Hosokawa H, Yamashita M, Motohashi S, Naka T, et al. Human Th1 differentiation induced by lipoarabinomannan/lipomannan from Mycobacterium bovis BCG Tokyo-172. Int Immunol 2008; 20: 849-860.
2. Kanska U, Budzynska R, Nevozhay D, Boratynski J. Preparation of mannan–protein conjugates using high‐temperature glycation. Biotechnol Appl Biochem 2008; 49: 57-64.
3. Proudfoot O, Esparon S, Tang C-K, Laurie K, Barr I, Pietersz G. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung. BMC Infect Dis 2015; 15: 101.
4. Huang X, Kakuda Y, Cui W. Hydrocolloids in emulsions: particle size distribution and interfacial activity. Food Hydrocoll 2001; 15: 533-542.
5. Horwitz W (2000). Official Methods of Analysis of Aoac International, Agricultural Chemicals, Contaminants, Drugs, Vol. 1 (Official Methods of Analysis of the association of official analytical chemists).
6. Ozdemir KG, Yılmaz H, Yılmaz S. In vitro evaluation of cytotoxicity of soft lining materials on L929 cells by MTT assay. J Biomed Mater Res B Appl Biomater 2009; 90: 82-86.
7. Aiyer Harini P, Ashok Kumar HG, Praveen Kumar G, Shivakumar N. An overview of immunologic adjuvants-A‎ review. J Vaccines Vaccin 2013; 4: 167.
8. Apostólico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: classification, modus operandi, and licensing. J Immunol Res 2016; 2016: 1459394.
9. Benito-Villalvilla C, Soria I, Subiza JL, Palomares O. Novel vaccines targeting dendritic cells by coupling allergoids to mannan. Allergo J Int 2018; 27: 256-262.
10. Bhamidi S (2009). Mycobacterial Cell Wall Arabinogalactan. In: Ullrich M, Ed. Bacterial Polysaccharides: Current Innovations and Future Trends, Horizon Scientific Press.
11. Busold S, Nagy NA, Tas SW, Van Ree R, De Jong EC, Geijtenbeek TBH. Various tastes of sugar: the potential of glycosylation in targeting and modulating human immunity via C-type lectin receptors. Front Immunol 2020; 11: 134.
12. Bystrický S, Paulovičová E, Machová E. Candida albicans mannan–protein conjugate as vaccine candidate. Immunol Lett 2003; 85: 251-255.
13. Apostólico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res 2016; 2016: 1459394.
14. De Gregorio E, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front Immunol 2013; 4: 214.
15. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186-6197.
16. Gonçalves C, Ferreira SA, Correia AL, Lopes C, Fleming CE, Rocha E, et al. Potential of mannan or dextrin nanogels as vaccine carrier/adjuvant systems. J Bioact Compat Polym 2016; 31: 453-466.
17. Chauhan N, Tiwari S, Iype T, Jain U. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators. Expert Rev Vaccines 2017; 16: 491-502.
18. Lima KM, dos Santos SA, Rodrigues Jr JM, Silva CL. Vaccine adjuvant: it makes the difference. Vaccine 2004; 22: 2374-2379.
19. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-496.
20. Petrovsky N, Cooper PD. Carbohydrate-based immune adjuvants. Expert Rev Vaccines 2011; 10: 523-537.
21. Yasar Yildiz S, Toksoy Oner E (2014). Mannan as a Promising Bioactive Material for Drug Nanocarrier Systems. Application of Nanotechnology in Drug Delivery. https://www.intechopen.com/chapters/46789
22. Correia-Neves M, Sundling C, Cooper A, Källenius G. Lipoarabinomannan in active and passive protection against tuberculosis. Front Immunol 2019; 10: 1968.
23. Turner J, Torrelles JB. Mannose-capped lipoarabinomannan in Mycobacterium tuberculosis pathogenesis. Pathog Dis 2018; 76: fty026.
24. Dao DN, Kremer L, Guérardel Y, Molano A, Jacobs WR, Porcelli SA, et al. Mycobacterium tuberculosis Lipomannan induces apoptosis and interleukin-12 production in Macrophages. Infect Immun 2004; 72: 2067-2074.
25. Wattanasiri C, Paha J, Ponpuak M, Ruchirawat S, Boonyarattanakalin S. Synthesis of synthetic mannan backbone polysaccharides found on the surface of Mycobacterium tuberculosis as a vaccine adjuvant and their immunological properties. Carbohydr Polym 2017; 175: 746-755.
Files
IssueVol 16 No 3 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v16i3.15767
Keywords
Mycobacterium bovis; Adjuvant; Mannan; Immunity
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Mardani R, Alavi A, Mousavi Nasab SD, Ahmadi N, Hossein Tehrani MJ, Shahali M, Doroud D. Immunogenicity of mannan derived from Mycobacterium bovis as a promising adjuvant in vaccine BCG. Iran J Microbiol. 2024;16(3):351-356.